Download PDF
Thromb Haemost 1989; 61(01): 106-110
DOI: 10.1055/s-0038-1646536
Original Article
Schattauer GmbH Stuttgart

Significance of Plasma Adenosine in the Antiplatelet Activity of Forskolin: Potentiation by Dipyridamole and Dilazep

Kailash C Agarwal
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
,
Beth A Zielinski
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
,
Ranjan S Maitra
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
› Author Affiliations
Further Information

Publication History

Received 26 May 1988

Accepted after revision 29 September 1988

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Forskolin, a plant (Coleus forskohlii) diterpene, inhibits ADP- induced (human: IC50, 2.3±1.0 μ;M; rat: IC50, 1.2±0.5 μM) and collagen-induced (human: IC50, 2.4±1.2 μM; rat: 0.6±0.2 μM) platelet aggregation in human and rat platelet-rich plasma (PRP). Human blood levels of adenosine (Ado) are low (100-300 nM) as compared to levels in rat plasma (7.55 ± 0.51 μM). Ado is a natural antiplatelet and vasodilatory agent produced by vascular endothelium, heart and other body tissues. If the plasma Ado is degraded by pretreatment of PRP with adenosine deaminase (ADA), forskolin inhibition on platelet aggregation is reduced by 2-4 fold both in human and rat blood. On the other hand, if the physiological steady state levels of Ado are maintained by collecting the blood in the presence of the inhibitors of ADA (2’-deoxycoformycin, dCF, 5 μM) and Ado uptake (dipyridamole, 10 μM or dilazep, 2 μM), forskolin inhibition (IC50, 3.2 μM) on platelet aggregation in human PRP is potentiated by 20-40 fold (IC50, 0.075-0.15 μM). Similar potentiated forskolin effect (IC50, 0.53 μM) is seen if the ADA-treated human PRP is replenished with a low level of Ado (50 nM) after ADA inactivation by dCF and Ado-uptake blockade by dilazep. If the plasma is replenished with a higher concentration of Ado (300 nM), greater potentiation is seen (IC50, 0.23 μM). Forskolin is 2-4 fold more inhibitory in rat PRP than in human PRP, partially due to the presence of higher levels of Ado in the rat plasma. These studies demonstrate an important role of plasma Ado in the antiplatelet activity of forskolin and this effect can be greatly potentiated by the clinically used drugs, dipyridamole and dilazep.

Key words

Platelet - Forskolin - Adenosine - Dipyridamole - Dilazep
 

  • References

  • 1 Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21: 680-687
    PubMedSearch in Google Scholar
  • 2 Agarwal KC, Parks Jr RE. Synergistic inhibition of platelet aggregation by forskolin plus PGE1 or 2-fluoroadenosine: Effects of 2’ ,5’-dideoxyadenosine and 5’-methylthioadenosine. Biochem Pharmacol 1982; 31: 3713-3716
    CrossrefPubMedSearch in Google Scholar
  • 3 Seamon K, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981; 256: 9799-9801
    PubMedSearch in Google Scholar
  • 4 Insel PA, Stengel D, Ferry N, Hanoune J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 1982; 257: 7485-7490
    PubMedSearch in Google Scholar
  • 5 FitzGerald GA. Drug therapy: dipyridamole. New Engl J Med 1987; 316: 1247-1257
    CrossrefPubMedSearch in Google Scholar
  • 6 Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozier G, Heinzel G. Pharmacokinetics of oral dipyridamole (persan- tine) and its effects on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229-234
    CrossrefPubMedSearch in Google Scholar
  • 7 Lenke D, Brock N, Zechel HJ. Zur Pharmakologie von 1,4-bis-[3-(3,4,5-trimethoxybenzoyl-oxy)-propyl]-perhydro-1,4-diazepin (dilazep I.N.N.), einer neuen koronaraktiven Substanz. Arzneim-Forsch (Drug Res) 1972; 22: 639-651
    PubMedSearch in Google Scholar
  • 8 Sollevi A, Torsell L, Owall A, Edlund A, Lagerkranser M. Levels and cardiovascular effects of adenosine in humans. In: Topics and Perspectives in Adenosine Research. Garlach E, Becker BF. (eds) Springer-Verlag; Heidelberg: 1987. pp 599-613
    Search in Google Scholar
  • 9 Pohl VJ, Brock N. Vergleichende Untersuchungen zur Hemmung des Adenosinabbaus in vitro durch Dilazep. Arzneim-Forsch (Drug Res) 1974; 24: 1901-1905
    PubMedSearch in Google Scholar
  • 10 Dawicki DD, Agarwal KC, Parks Jr RE. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res 1986; 43: 161-175
    CrossrefPubMedSearch in Google Scholar
  • 11 Dawicki DD, Agarwal KC, Parks Jr RE. Adenosine metabolism in human whole blood: Effects of nucleoside transport inhibitors and phosphate concentration. Biochem Pharmacol 1988; 37: 621-626
    CrossrefPubMedSearch in Google Scholar
  • 12 Drury A, Szent-Gyorgi A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol. (London): 1929. 68 213-237
    Search in Google Scholar
  • 13 Born GV R, Haslam RJ, Goldman M, Lowe RD. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man. Nature 1965; 205: 678-680
    CrossrefPubMedSearch in Google Scholar
  • 14 Agarwal KC. Adenosine and platelet function. In: Role of Adenosine in Cerebral Metabolism and Blood Flow. Stefanovich V, Okyayuz-Baklouti I. (eds) VSP BV Press; Utrecht: 1988. pp 107-124
    Search in Google Scholar
  • 15 Agarwal KC. New insights into the antiplatelet activity of forskolin: Role of plasma adenosine and species differences. Thromb Haemostas 1987; 58: 212 (Abstr)
    PubMedSearch in Google Scholar
  • 16 Agarwal KC, Haskel EJ, Parks Jr RE. Effects of adenosine analogs and adenine nucleotides on adenosine-5’-diphosphate-induced rat platelet aggregation. Biochem Pharmacol 1980; 29: 1799-1805
    CrossrefPubMedSearch in Google Scholar
  • 17 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
    CrossrefPubMedSearch in Google Scholar
  • 18 Cardinal DC, Flower RJ. The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158
    CrossrefPubMedSearch in Google Scholar
  • 19 Sato T, Ui M. A sensitive radioimmunoassay for adenosine. In: Physiology and Pharmacology of Adenosine. Daly JW, Kuroda Y, Phillis JW, Shimizu H, Ui M. (eds) Raven Press; New York: 1983. PP 1-11
    Search in Google Scholar
  • 20 Paterson AR P, Jackobs ES, Harley ER, Fu N, Robins MJ, Cass CE. Inhibition of nucleoside transport. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubio R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 203-220
    Search in Google Scholar
  • 21 Pearson JD, Hellewell PG, Gordon JL. Adenosine uptake and adenine nucleotide metabolism by vascular endothelium. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubion R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 333-345
    Search in Google Scholar
  • 22 Berne RM, Winn HR, Knabb RM, Ely SW, Rubio R. Blood flow regulation by adenosine in heart, brain and skeletal muscle. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubio R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 293-317
    Search in Google Scholar
  • 23 Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol 1981; 3: 1-13
    CrossrefPubMedSearch in Google Scholar
  • 24 Agarwal KC, Buckley RS, Parks Jr RE. Role of plasma adenosine in the antiplatelet action of HL-725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res 1987; 47: 191-200
    CrossrefPubMedSearch in Google Scholar
  • 25 Jarvis SM, Hammond JR, Paterson AR P, Clanachan AS. Species differences in nucleoside transport: A study of uridine transport and nitrobenzylthioinosine binding by mammalian erythrocytes. Biochem J 1983; 208: 83-88
    PubMedSearch in Google Scholar